Investigating drug effects on cancer-causing gene fusion proteins
Official title: Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer
Funded at Talus Bioscience, INC. · NIH-10869995 · Data updated 2026-11-12
This study is looking at how specific proteins that can cause cancer respond to different medications, with the hope of finding better treatments for people with certain types of leukemia.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Talus Bioscience, INC. NIH-funded |
| Lab location | 1 site (Seattle, UNITED STATES) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44CA268146-03 |
| Project ID | NIH-10869995 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children and young adults diagnosed with leukemia or other cancers associated with oncogenic gene fusions.
✕Less likely to help
Patients with cancers not related to gene fusions or those outside the age range of 0-21 may not benefit from this research.
What this research studies
This research focuses on understanding how certain gene fusion proteins, which can drive cancer, respond to various drugs. By using a novel technique called ChESS-DIA, researchers will analyze how these proteins interact with small molecules in different cell types. This approach aims to overcome previous challenges in targeting these proteins for treatment, particularly in types of leukemia. The goal is to develop effective therapies for patients with oncogenic gene fusions.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with specific types of cancer caused by gene fusions.
How similar studies have gone: Other research has shown promise in targeting gene fusion proteins, but this specific approach using ChESS-DIA is relatively novel.
Where this research is happening
-
Talus Bioscience, INC.
Seattle, United States Active
Researchers
- Principal investigator: Federation, Alexander — Talus Bioscience, INC.
- Study coordinator: Federation, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.